Friday, 9 October 2026European Markets
ExploreSearch
ViaNews EU
IndexesMarket

AEX-Index Slides By 2% In The Last 24 Hours

Loading stream...

(VIANEWS) - AEX-Index (^AEX) has been up by 2.43% for the last session's close. At 17:50 EST on Tuesday, 15 October, AEX-Index (^AEX) is €900.17.

AEX-Index Range

Concerning AEX-Index's daily highs and lows, it's 1.64% down from its trailing 24 hours low of €915.21 and 2.44% down from its trailing 24 hours high of €922.67.

Regarding AEX-Index's yearly highs and lows, it's 26.48% up from its 52-week low and 5.16% down from its 52-week high.

Volatility

AEX-Index's last week, last month's, and last quarter's current intraday variation average was 0.34%, 0.13%, and 0.74%, respectively.

AEX-Index's highest amplitude of average volatility was 0.58% (last week), 0.62% (last month), and 0.74% (last quarter), respectively.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AEX-Index's is considered to be oversold (<=20).

More news about AEX-Index (^AEX).

Categories

IndexesMarket

Tags

AEX-IndexIndexPrice DownIndex NowINDICES Price Down^AEXIndicesWorld Indices
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,365 source documents archived
Query this data → isubstrate.com